Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.52 |
| ▸ | SCN1A | P35498 | 5/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864786 | 0.89 | SCN1A (0.55) | SCN8ASCN1AGAASIGMAR1 | |
| SCHEMBL5865015 | 0.87 | SCN8A (0.59) | SCN8ASCN1AROCK1ROCK2CCR2 | |
| SCHEMBL21306436 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2OPRK1HRH3ROCK1GAA | |
| SCHEMBL4119205 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2OPRK1HRH3GAASIGMAR1 | |
| SCHEMBL5858933 | 0.83 | HRH3 (0.60) | SMN1; SMN2OPRK1HRH3ROCK1GAA | |
| SCHEMBL5864782 | 0.83 | HRH3 (0.48) | SMN1; SMN2SCN8ASCN1AHRH3GAA | |
| SCHEMBL5864969 | 0.82 | ALDH1A1 (0.43) | SMN1; SMN2HRH3GAA | |
| SCHEMBL12226765 | 0.81 | UTS2R (0.69) | OPRK1SIGMAR1UTS2RMCHR1 | |
| SCHEMBL3022526 | 0.81 | HRH3 (0.71) | SMN1; SMN2OPRK1HRH3ROCK1GAA | |
| SCHEMBL13676235 | 0.80 | OPRK1 (0.70) | SMN1; SMN2OPRK1HRH3ROCK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | SMN1; SMN2 4174/4885OPRK1 1490/4885SCN8A 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.